ACT


Actavis plc (ACT): A Leader In ‘Growth Pharma’

  Dublin-based generic and specialty drug company Actavis plc (NYSE:ACT) is a pharma deal-maker. Much of Actavis’ growth as a company has been …

New Year Kicks Off With New Fears To Keep Investors On Edge

As widely expected, the new year has begun with a lot of volatility on high trading volume, as investors fear more than just …

The Best Long Bets Made By Major Hedge Funds In 2014; Apple Marks A Winning Year

This has not been an easy year for hedge funds. The most popular hedge fund strategy, long/short equity, which usually churns out an …

Hedge Funds Buy ACT, BABA, ABBV; Dump AAPL, BIDU

S&P Capital IQ, a leading provider of multi-asset class research data and insights, has announced the release of its review of 2014 Q3 …

Actavis Says ‘Let’s Make A Deal’

I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …

A Bizarre Pharma Love Triangle

Back on July 3rd of this year, I wrote about a good find in pharma called Salix Pharmaceuticals (NASDAQ:SLXP). Salix Pharmaceuticals is a …

Actavis Remains One Of Our Top Picks Going Into Its 2Q14 Earnings Call, Says Cannacord

In a research note released yesterday, Cannacord Genuity analyst Corey Davis reaffirmed a Buy rating on Actavis (ACT) with a price target of …

Actavis Receives New Coverage From Canaccord Analyst Corey Davis

In a research report issued Thursday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Actavis plc (ACT) and a price target of $275.00 a share, representing a potential …